Australia to Include 4 New Hepatitis C Drugs on National Formulary

Australia’s Pharmaceutical Benefits Scheme has listed four new hepatitis C drugs on its subsidized formulary.

Priced between $6.20 and $38.30 per prescription, the drugs include Gilead’s Sovaldi and Harvoni, Bristol-Myers Squibb’s Daklinza and Clinect’s ribavirin.

The drugs are available to patients over the age of 18 with chronic hepatitis C, and a complete course of treatment ranges from eight to 24 weeks, depending on the person’s genotype and treatment history.

In the U.S., Sovaldi costs roughly $1,000 per pill.